Skip to content
    Inve.money
    Earnings calls

    Fredun Pharma concall ledger

    Every earnings call for 539730 — management tone, guidance, KPIs and promise tracking, quarter by quarter.

    539730 · 4 transcripts · Healthcare · latest Q4 FY26
    Q4 FY26Published 10 Jun 2026Call held 10 Jun 2026

    539730 Q4 FY26 Earnings Call Transcript & Analysis

    FY26 EBITDA₹94.79 cr+72% YoYFY26 EBITDA Margin14.83%FY26 Net Profit₹33.21 cr+60% YoYFY26 Total Income₹639.12 cr+40% YoY

    FY26 EBITDA ₹95 cr (+72% YoY); FY26 EBITDA Margin 14.83%; FY26 Net Profit ₹33 cr (+60% YoY). Q4 FY26 Total Income of INR 213 crores, up 27.27% YoY.

    Read full transcript & analysis
    Q3 FY26Published 12 Feb 2026Call held 12 Feb 2026

    539730 Q3 FY26 Earnings Call Transcript & Analysis

    Q3 Total Income₹160.92 cr+57% YoYQ3 EBITDA₹26.34 cr+99% YoYQ3 EBITDA Margin16%Q3 Net Profit₹10.48 cr+96% YoYQ3 Net Profit Margin7%

    Q3 Total Income ₹161 cr (+57% YoY); Q3 EBITDA ₹26 cr (+99% YoY); Q3 EBITDA Margin 16.0%. Q3 FY26 total income stood at INR160.92 crores, registering a strong growth of 57% year-on-year.

    Read full transcript & analysis
    Q2 FY26Published 11 Nov 2025Call held 11 Nov 2025

    539730 Q2 FY26 Earnings Call Transcript & Analysis

    EBITDA₹22.34 cr+60% YoYEBITDA Margin15.37%Net Profit₹9.73 cr+128% YoYTotal Income₹145.29 cr+35% YoY

    EBITDA (Q2 FY26) ₹22 cr (+60% YoY); EBITDA Margin (Q2 FY26) 15.37%; Net Profit (Q2 FY26) ₹10 cr (+128% YoY). Q2 FY26 Total income stood at INR 145.29 crores, growing by 35% year-on-year.

    Read full transcript & analysis